Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jos H Beijnen

Showing results (1-10 of 890) with videos related to

Pageof 89
Sort By:
Clinical Pharmacology in Drug Development|June 24, 2020
Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in OncologyJeroen Roosendaal, Hilde Rosing, Jos H Beijnen
Current Clinical Pharmacology|May 11, 2010
Selected new developments in oncologyJos H Beijnen, Jan H M Schellens
Clinical Pharmacokinetics|October 16, 2020
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug ActionEllen J B Derissen, Jos H Beijnen
Mass Spectrometry Reviews|December 16, 2004
Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugsEllen Stokvis, Hilde Rosing, Jos H Beijnen
Rapid Communications in Mass Spectrometry : RCM|January 13, 2005
Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?Ellen Stokvis, Hilde Rosing, Jos H Beijnen
Drugs in R&D|April 18, 2020
Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in OncologyJeroen Roosendaal, Hilde Rosing, Jos H Beijnen
The Lancet. Oncology|August 4, 2004
Drug interactions in oncologyJos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Personalized medicine in oncology: a personal view with myths and factsJos H Beijnen, Jan H M Schellens
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 3, 2010
'Flooding' of the lungs and severe dyspnea in a patient with bronchoalveolar carcinomaRon J Keizer, Jos H Beijnen, Paul Baas
Current Clinical Pharmacology|April 22, 2010
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agentsSuzanne Leijen, Jos H Beijnen, Jan H M Schellens
Pageof 89

Showing results (1-10 of 890) with videos related to

Sort By:
Pageof 89
Clinical Pharmacology in Drug Development|June 24, 2020
Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in OncologyJeroen Roosendaal, Hilde Rosing, Jos H Beijnen
Current Clinical Pharmacology|May 11, 2010
Selected new developments in oncologyJos H Beijnen, Jan H M Schellens
Clinical Pharmacokinetics|October 16, 2020
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug ActionEllen J B Derissen, Jos H Beijnen
Mass Spectrometry Reviews|December 16, 2004
Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugsEllen Stokvis, Hilde Rosing, Jos H Beijnen
Rapid Communications in Mass Spectrometry : RCM|January 13, 2005
Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?Ellen Stokvis, Hilde Rosing, Jos H Beijnen
Drugs in R&D|April 18, 2020
Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in OncologyJeroen Roosendaal, Hilde Rosing, Jos H Beijnen
The Lancet. Oncology|August 4, 2004
Drug interactions in oncologyJos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Personalized medicine in oncology: a personal view with myths and factsJos H Beijnen, Jan H M Schellens
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 3, 2010
'Flooding' of the lungs and severe dyspnea in a patient with bronchoalveolar carcinomaRon J Keizer, Jos H Beijnen, Paul Baas
Current Clinical Pharmacology|April 22, 2010
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agentsSuzanne Leijen, Jos H Beijnen, Jan H M Schellens
Pageof 89